Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Novartis is mitigating a potential threat from the BIOSECURE Act. A Neurocrine drug from Takeda posted a trial win. Enhertu nears a HER2-low readout.
Angus Liu
Apr 26, 2024 5:45am
Novo Nordisk grilled by Sanders over steep GLP-1 pricing
Apr 25, 2024 2:58pm
Sponsored
MAIC Methodology Matters: Comparing BRUKINSA vs Acalabrutinib in R/R CLL
Apr 1, 2024 8:00am
BMS leans on long-term growth drivers to dodge IRA impacts
Apr 25, 2024 12:57pm
Sponsored
The biopharma “brain drain”: Finding talent to fuel innovation
Jan 26, 2024 8:00am
Sanofi is going all in on Dupixent's next potential nod in COPD
Apr 25, 2024 12:37pm